<code id='79C462BA92'></code><style id='79C462BA92'></style>
    • <acronym id='79C462BA92'></acronym>
      <center id='79C462BA92'><center id='79C462BA92'><tfoot id='79C462BA92'></tfoot></center><abbr id='79C462BA92'><dir id='79C462BA92'><tfoot id='79C462BA92'></tfoot><noframes id='79C462BA92'>

    • <optgroup id='79C462BA92'><strike id='79C462BA92'><sup id='79C462BA92'></sup></strike><code id='79C462BA92'></code></optgroup>
        1. <b id='79C462BA92'><label id='79C462BA92'><select id='79C462BA92'><dt id='79C462BA92'><span id='79C462BA92'></span></dt></select></label></b><u id='79C462BA92'></u>
          <i id='79C462BA92'><strike id='79C462BA92'><tt id='79C462BA92'><pre id='79C462BA92'></pre></tt></strike></i>

          Home / entertainment / hotspot

          hotspot


          hotspot

          author:comprehensive    Page View:383
          Jeremey Wyatt ActiGraph

          As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

          The Pensacola, Fla.-based company creates  devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

          advertisement

          There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In